The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Enzalutamide monotherapy: Extended follow-up of a phase II study in hormone-naive prostate cancer patients.
Bertrand Tombal
Consultant or Advisory Role - Amgen; Bayer; Ferring; Sanofi
Honoraria - Amgen; Bayer; Ferring; Sanofi
Michael Borre
No relevant relationships to disclose
Per Rathenborg
No relevant relationships to disclose
Patrick Werbrouck
No relevant relationships to disclose
Hendrik Van Poppel
No relevant relationships to disclose
Axel Heidenreich
No relevant relationships to disclose
Peter Iversen
Employment or Leadership Position - Astellas Pharma
Honoraria - Travel to advisory board meetings
Other Remuneration - Astellas Pharma
Johan Braeckman
No relevant relationships to disclose
Jiri Heracek
No relevant relationships to disclose
Edwina Baskin-Bey
Employment or Leadership Position - Astellas Pharma
Taoufik Ouatas
Employment or Leadership Position - Astellas Pharma
Frank Perabo
Employment or Leadership Position - Astellas Pharma
De Phung
Employment or Leadership Position - Astellas Pharma
Matthew R. Smith
Consultant or Advisory Role - Astellas Pharma; Janssen-Ortho